0
2021
Telmisartan Market

Telmisartan Market

by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020-2027

Report Code: A10293
Pages: 225
Feb 2021 | 5055 Views
Author(s) : Sagar M, Sushant T , Onkar S
Tables: 22
Charts: 19
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Telmisartan Market

Request Now !

Telmisartan Market Statistics 2020-2027:

The global telmisartan market size was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027.

Telmisartan drug is a non-peptide angiotensin receptor blockers (ARBs) intended for treatment of hypertension and cardiovascular risk reduction. It is used alone or in combination with other agents such as hydrochlorothiazide and amlodipine. Telmisartan is available in three different strengths tablets such as 20 mg, 40 mg, and 80 mg. Telmisartan is indicated for the treatment of mild to moderate hypertension condition. It works by relaxing blood vessels so that blood can flow more easily. However, it has some side effects which include dizziness, cough, lightheadedness, sinus pain and others.

Telmisartan-Market,-2020-2027

Increase in prevalence of high blood pressure (hypertension), surge in geriatric population, and rise in government initiatives for spreading awareness about blood pressure diseases are the factors that are expected to drive the growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) joined in campaigns such as ‘May Measurement Month & World Hypertension Day’ for making awareness among population about hypertension and its management. In addition, rise in marketing approvals for generic versions of telmisartan, increase in sedentary lifestyle, and surge in incidences of chronic diseases such as diabetes and kidney disease, are expected to drive the growth of the telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.

The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Telmisartan tablets manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shut down in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to supply shortage.

Telmisartan Market Segmentation  

The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Telmisartan Market
By Indication

Your browser does not support the canvas element.

Hypertension segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Telmisartan Market Segment review 

Presently, on the basis of indication, the hypertension is a major revenue contributor, and is projected to grow significantly during the forecast period. Increase in prevalence of hypertension, rise in demand for antihypertensive drugs, and surge in awareness about hypertension and its management by organizing global level campaigns boosts the growth of the market. Moreover, availability of better treatment options for hypertension, increase in number of product approvals, and rise in geriatric population suffering from hypertension are the other factors that drive the growth of the market.

Depending on distribution channel, the hospital pharmacies segment is the major shareholder in the global telmisartan market, owing to surge in number of hospitalized hypertension patients, increase in number of hospital pharmacies worldwide, and improvement in structure of hospital pharmacies in the emerging countries such as China and India. Moreover, telmisartan drug is a prescription-based medication, which is mostly prescribed by the specialized healthcare professionals available in hospitals, thereby boosting the growth of this segment. On the contrary, the online pharmacies segment is expected to exhibit the highest growth rate during the forecast period, owing to increase in awareness of online pharmacy, rise in preference for online purchasing of drugs, and surge in the use of internet across the globe. Moreover, online pharmacies offer various advantages such as more convenience, fewer expenses, easy access to patient reviews, and price comparisons, which drive the market growth.

Telmisartan Market
By Distribution Channel

Your browser does not support the canvas element.

Hospital Pharmacies segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific telmisartan market  

Asia-Pacific presents lucrative opportunities for key players operating in the telmisartan market, owing to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases, rise in number of hospital pharmacies and online pharmacies, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the telmisartan market in the region.

The key players profiled in this report include Abbott Laboratories, Aurobindo Pharma, Boehringer Ingelheim International GmbH, Cipla Inc., Glaxosmithkline Plc (GSK), Mylan N.V., Sanofi, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila.

Telmisartan Market
By Region

2027
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 5.2% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the telmisartan market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers telmisartan market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global telmisartan market growth.

Telmisartan Market Report Highlights

Aspects Details
BY INDICATION
  • Hypertension
  • Cardiovascular Risk Reduction
BY DISTRIBUTION CHANNEL
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies
BY REGION
  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players ABBOTT LABORATORIES, AUROBINDO PHARMA, BOEHRINGER INGELHEIM INTERNATIONAL GMBH, CIPLA INC, GLAXOSMITHKLINE PLC (GSK), MYLAN N.V, SANOFI, SUN PHARMACEUTICAL INDUSTRIES LIMITED, TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS), ZYDUS CADILA
 

Loading Table Of Content...


 
 

Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with hydrochlorothiazide and amlodipine for treatment of hypertension and cardiovascular risk reduction. It is available in different strengths tablets such as 20 mg, 40 mg, and 80 mg.

The utilization of telmisartan drug has witnessed significant growth, owing to surge in incidence of hypertension and cardiovascular diseases worldwide. Furthermore, other factors such as rise in geriatric population suffering from high blood pressure, surge in generic telmsartan tablets approvals, surge in awareness related to complication of hypertension, and sedentary lifestyle are the factors that fuel the growth of the market. However, drug shortages are expected to restrain the growth of the telmisartan market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Telmisartan is indicated for the treatment of mild to moderate hypertension and cardiovascular risk reduction.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 6.0%. This is due to increase in number of hypertension patients in emerging economies, rise in adoption of antihypertensive drugs, development of the R&D sector, rise in healthcare reforms, and technological advancements in pharmaceutical drug manufacturing, Moreover, rise in demand for telmisartan tablets, and surge in funding from government and non-government sectors to create awareness about hypertension and cardiovascular diseases.

A. The total market value of Telmisartan market is $3,453.13 million in 2019.

A. The forcast period for Telmisartan market is 2020 to 2027

A. Top companies such as Abbott Laboratories, Boehringer Ingelheim International GmbH, Glaxosmithkline Plc (GSK), Mylan N.V., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Zydus Cadila held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. The market value of Telmisartan market in 2020 is $3,366.81 million.

A. Hypertension segment is the most influencing segment owing to surge in prevalence of hypertension across the globe, rise in awareness related to the use of telmisartan for the treatment of high blood pressure.

A. The base year is 2019 in Telmisartan market

A. The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Telmisartan Market

Start reading instantly.
This Report and over 19,668+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Feb 2022 - Feb 2023)
  • Library
    Membership

  • $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers